RT Journal Article
SR Electronic
T1 Leveraging DNA Methylation to Predict Treatment Response in Major Depressive Disorder: A Critical Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.01.23299308
DO 10.1101/2023.12.01.23299308
A1 Dahrendorff, Jan
A1 Currier, Glenn
A1 Uddin, Monica
YR 2023
UL http://medrxiv.org/content/early/2023/12/02/2023.12.01.23299308.abstract
AB Background Major depressive disorder (MDD) is a debilitating and prevalent mental disorder with a high disease burden. Despite a wide array of different treatment options, many patients do not respond to initial treatment attempts. Selection of the most appropriate treatment remains a significant clinical challenge in psychiatry, highlighting the need for the development of biomarkers with predictive utility. Recently, the epigenetic modification DNA methylation (DNAm) has emerged to be of great interest as a potential predictor of MDD treatment outcomes. Here we review efforts to date that seek to identify DNAm signatures associated with treatment response in individuals with MDD.Methods Searches were conducted in the databases PubMed, Scopus, and Web of Science with the concepts and keywords major depressive disorder, DNA methylation, antidepressants, psychotherapy, cognitive behavior therapy, electroconvulsive therapy, transcranial magnetic stimulation, and brain stimulation therapies.Results We identified 31 studies implicating DNAm patterns associated with MDD treatment outcomes. The majority of studies (N=25) are focused on selected target genes exploring treatment outcomes in pharmacological treatments (N=22) with a few studies assessing treatment response to electroconvulsive therapy (N=3). Additionally, there are few genome-scale efforts (N=6) to characterize DNAm patterns associated with treatment outcomes.Limitations There is a relative dearth of studies investigating DNAm patterns in relation to psychotherapy, electroconvulsive therapy, or transcranial magnetic stimulation; importantly, most existing studies have limited sample sizes.Conclusions Given the heterogeneity in both methods and results of studies to date, there is a need for additional studies before existing findings can inform clinical decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a College of Public Health (COPH) Internal Award. J. Dahrendorff was supported by the COPH Doctoral Fellowship of the University of South Florida.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript